A few months after receiving FDA clearance, CarnaLife Holo was spotlighted by the influential US portal CardiovascularBusiness.com in the context of its integration with GE HealthCare echocardiographs.
A few months after receiving FDA clearance, CarnaLife Holo has been spotlighted by the influential industry portal CardiovascularBusiness.com.
Cardiovascular Business is a US outlet publishing news on the business and technology of cardiovascular medicine. The portal focuses on the business and economic aspects behind the most important clinical, interventional, surgical and information technologies, as well as the pharmaceuticals and related products that are key to success in cardiovascular practice.
Our mixed reality 3D holographic imaging technology, CarnaLife Holo, was presented in the context of its integration with GE HealthCare echocardiographs. The integration enables the display of, and interaction with, live 3D holograms of the heart through a direct connection to the echocardiograph.
Read the full article on cardiovascularbusiness.comMore about CarnaLife HoloThe latest on MedApp, CarnaLife Holo and our deployments.
MedApp's augmented reality and AI-based solutions can support physicians in military hospitals and in operational conditions. The company holds an NCAGE code, and its subsidiary has applied for a licence to trade in military-purpose technology.
Read moreThe Management Board informs about actions taken by the Social Insurance Institution (ZUS) regarding the Issuer's liabilities and the application submitted to pay the amounts due in instalments. Maintaining operational continuity remains the priority.
Read moreOn 27–30 October 2025 MedApp presents CarnaLife Holo at the Global Health Exhibition in Riyadh – one of the largest healthcare events in the world. Find us in Hall H1A, stand PODS64.
Read more
